World's Largest Resource for Cardiovascular Perfusion

Perfusion StaffingPerfusion Staffing
   +1 888-499-5672Login
Perfusion NewswireBiologics ZoneAutologous Platelet Rich Fibrin in the Treatment of Mandibular Degree Ii Furcation Defects: A Randomized Clinical Trial

Autologous Platelet Rich Fibrin in the Treatment of Mandibular Degree Ii Furcation Defects: A Randomized Clinical Trial

Biologics Zone, Blood Management, Main Zone, Mobile Zone

Background: Platelet rich fibrin (PRF), consists of an intimate assembly of cytokines, glycanic chains, and structural glycoproteins enmeshed within a slowly polymerized fibrin network, has the potential of accelerating soft and hard tissue healing. The present double-blind randomized study is designed to evaluate the effectiveness of autologous PRF in the treatment of mandibular degree II furcation defects compared with open flap debridement (OFD).


Methods: Using a split-mouth design, 18 subjects with 36 mandibular degree II furcation defects were randomly allotted and treated either with autologous PRF and OFD or OFD. Plaque index (PI), sulcus bleeding index (SBI), probing depth, relative vertical and horizontal clinical attachment level, gingival marginal level and radiographic bone defect were recorded at baseline and 9 months post-operatively. Comparison between indices between the test and control groups was performed using the paired t test except for PI and SBI data (Chi-square test).


Results: All the clinical and radiographic parameters showed statistically significant improvement at the sites treated with PRF as compared with those with OFD.


Conclusion: Within the limitation of this study, significant improvement with autologous PRFimplies its role as a regenerative material in the treatment of furcation defects.

Leave a Reply

You may also like
COVID-19, ECMO Zone, Perfusion Zone, Tiny Perfusion Letter

Six-Month Survival After Extracorporeal Membrane Oxygenation for Severe COVID-19

The present findings suggested that about half of adult patients with severe COVID-19–related ARDS can be managed successfully with ECMO with sustained results at six months. Decreased arterial pH before ECMO was associated significantly with early mortality. Therefore, the authors hypothesized that initiation of ECMO therapy before severe metabolic derangements subset may improve survival rates significantly in these patients. These results should be viewed in the light of a strict patient selection policy and may not be replicated in patients with advanced age or multiple comorbidities.

Join TodayJoin Today